Fresenius Kabi recalls Rifampin; China's 3SBio buys some small molecule manufacturing;

> Fresenius Kabi is voluntarily recalling two lots, or 7,593 vials, of Rifampin because they were out of specification for impurities and color. Recall

> Qualitest Pharmaceuticals is recalling 47,376 bottles of hydroxyzine hydrochloride because some identification codes are unreadable. Notice

> Chinese biotech 3SBio has acquired Zhejiang Wansheng Pharmaceutical for RMB 528 million ($85 million), in part to get its expertise in small molecule manufacturing. Release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.